Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.
Bristol-Myers Squibb and development partner bluebird bio have filed their multiple myeloma CAR-T with the FDA, the final part of a three-drug “bet” that was a sweetener following its $74 b
Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
